Loading…
Loading…
ONPH does not currently pay a dividend.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for ONPH and 80,000+ other tickers.
See exactly how ONPH's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for ONPH and 80,000+ other tickers.
Oncology Pharma Inc. is a pharmaceutical firm specializing in oncology, dedicated to the development, manufacturing, and commercialization of therapeutic agents. The company has a collaborative and licensing agreement with Kalos Therapeutics Inc. to explore treatment possibilities for the COVID-19 virus. Originally incorporated in 1993, the company was known as SourcingLink.net Inc. until it rebranded as Oncology Pharma Inc. in June 2019. Its operations are based in San Francisco, California.
Rafael (NYSE: RFL - Get Free Report) and Oncology Pharma (OTCMKTS:ONPH - Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, earnings, profitability and institutional ownership. Earnings and Valuation This table compares Rafael and
Oncology Pharma (OTCMKTS:ONPH - Get Free Report) and Larimar Therapeutics (NASDAQ: LRMR - Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, institutional ownership, valuation, dividends and profitability. Profitability This table compares Oncology Pharma and
SAN FRANCISCO, CA / ACCESSWIRE / October 15, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) Pursuant to previously announced press release, Oncology Pharma, Inc. (the "Company") has retained the services of DBBMcKennon, LLC, a PCAOB Certified Public Accounting Firm. The Company has retained the firm to conduct an audit of its financials in order to become compliant with SEC reporting standards as it look towards its intended NASDAQ Capital Markets Listing.
SAN FRANCISCO, CA / ACCESSWIRE / September 13, 2021 / Oncology Pharma, Inc. (OTC PINK:ONPH). In keeping with management's commitment to continue implementation of Oncology Pharma's ("the Company") capital formation plan, the Company has obtained, received and segregated all funds necessary to execute the first phase of the development project of a nanoemulsion of dactinomycin, with the initial tranche released as scheduled.
SAN FRANCISCO, CA / ACCESSWIRE / August 23, 2021 / Oncology Pharma, Inc. (OTC PINK:ONPH) defines its objective and strategy for recently signed Co-Development deal. The primary goal of the Co-Development plan is to bring new pharmaceutical drug formulations to market with a focused approach that aims to reduce overall costs and time to commercialization.